Lim LL, Tan AT, Moses K, Rajadhyaksha V, Chan SP. Place of sodium-glucose cotransporter-2 inhibitors in East Asian subjects with type 2 diabetes mellitus: insights into the management of Asian phenotype. J Diabetes Compl. 2017;31(2):494–503.

Article  PubMed  Google Scholar 

Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, Colagiuri S, Guariguata L, Motala AA, Ogurtsova K, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the international diabetes federation diabetes atlas, 9(th) edition. Diabetes Res Clin Pract. 2019;157:107843.

Article  PubMed  Google Scholar 

Lima JE, Moreira NC, Sakamoto-Hojo ET. Mechanisms underlying the pathophysiology of type 2 diabetes: from risk factors to oxidative stress, metabolic dysfunction, and hyperglycemia. Mutat Research/Genetic Toxicol Environ Mutagen. 2022;874:503437.

Article  Google Scholar 

Demir S, Nawroth PP, Herzig S, Ekim Üstünel B. Emerging targets in type 2 diabetes and diabetic complications. Adv Sci (Weinh). 2021;8(18):e2100275.

Article  PubMed  Google Scholar 

Shi LJ, Tang X, He J, Shi W. Genetic evidence for a causal relationship between hyperlipidemia and type 2 diabetes in mice. Int J Mol Sci 2022, 23(11).

Korneva V, Kuznetsova T, Julius U. The role of cumulative LDL cholesterol in cardiovascular disease development in patients with Familial hypercholesterolemia. J Pers Med 2022, 12(1).

Bianconi V, Banach M, Pirro M. Why patients with Familial hypercholesterolemia are at high cardiovascular risk? Beyond LDL-C levels. Trends Cardiovasc Med. 2021;31(4):205–15.

Article  CAS  PubMed  Google Scholar 

Thomas H, Diamond J, Vieco A, Chaudhuri S, Shinnar E, Cromer S, Perel P, Mensah GA, Narula J, Johnson CO, et al. Global atlas of cardiovascular disease 2000–2016: the path to prevention and control. Glob Heart. 2018;13(3):143–63.

Article  PubMed  Google Scholar 

Kim BY, Won JC, Lee JH, Kim HS, Park JH, Ha KH, Won KC, Kim DJ, Park KS. Diabetes fact sheets in korea, 2018: an appraisal of current status. Diabetes Metab J. 2019;43(4):487–94.

Article  PubMed  PubMed Central  Google Scholar 

Hedayatnia M, Asadi Z, Zare-Feyzabadi R, Yaghooti-Khorasani M, Ghazizadeh H, Ghaffarian-Zirak R, Nosrati-Tirkani A, Mohammadi-Bajgiran M, Rohban M, Sadabadi F. Dyslipidemia and cardiovascular disease risk among the MASHAD study population. Lipids Health Dis. 2020;19:1–11.

Article  Google Scholar 

Bawah AT, Darko R, Abaka-Yawson A, Seini MM, Kinanyok S, Adusei S. Dyslipidemia and its associated factors in patients with type 2 diabetes mellitus. J Public Health. 2021;29:985–91.

Article  Google Scholar 

Patel TP, Rawal K, Bagchi AK, Akolkar G, Bernardes N, Dias DS, Gupta S, Singal PK. Insulin resistance: an additional risk factor in the pathogenesis of cardiovascular disease in type 2 diabetes. Heart Fail Rev. 2016;21:11–23.

Article  CAS  PubMed  Google Scholar 

Poli A, Catapano AL, Corsini A, Manzato E, Werba JP, Catena G, Cetin I, Cicero AFG, Cignarella A, Colivicchi F, et al. LDL-cholesterol control in the primary prevention of cardiovascular diseases: an expert opinion for clinicians and health professionals. Nutr Metab Cardiovasc Dis. 2023;33(2):245–57.

Article  CAS  PubMed  Google Scholar 

Wang N, Woodward M, Huffman MD, Rodgers A. Compounding benefits of Cholesterol-Lowering therapy for the reduction of major cardiovascular events: systematic review and Meta-Analysis. Circ Cardiovasc Qual Outcomes. 2022;15(6):e008552.

Article  PubMed  Google Scholar 

Yu J, Liu X, Chen S, Liu Y, Liu H, Zheng H, Yang N, Wu S, Li Y. Effects of low-density lipoprotein cholesterol on cardiovascular disease and all-cause mortality in elderly patients (≥ 75 years old). Endocrine. 2022;75(2):418–26.

Article  CAS  PubMed  Google Scholar 

Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097–107.

Article  CAS  PubMed  Google Scholar 

Brautbar A, Ballantyne CM. Pharmacological strategies for Lowering LDL cholesterol: Statins and beyond. Nat Reviews Cardiol. 2011;8(5):253–65.

Article  CAS  Google Scholar 

Pirillo A, Norata GD, Catapano AL. LDL-Cholesterol-Lowering therapy. Handb Exp Pharmacol. 2022;270:73–101.

CAS  PubMed  Google Scholar 

Bi L, Yi J, Wu C, Hu S, Zhang X, Lu J, Liu J, Zhang H, Yang Y, Cui J, et al. Atherosclerotic cardiovascular disease risk and Lipid-Lowering therapy requirement in China. Front Cardiovasc Med. 2022;9:839571.

Article  PubMed  PubMed Central  Google Scholar 

Stulc T, Ceška R, Gotto AM Jr. Statin intolerance: the clinician’s perspective. Curr Atheroscler Rep. 2015;17(12):69.

Article  PubMed  PubMed Central  Google Scholar 

2019 ESC/EAS guidelines for the. Management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Atherosclerosis. 2019;290:140–205.

Google Scholar 

Chai M, He Y, Zhao W, Han X, Zhao G, Ma X, Qiao P, Shi D, Liu Y, Han W, et al. Efficacy and safety of Tafolecimab in Chinese patients with heterozygous Familial hypercholesterolemia: a randomized, double-blind, placebo-controlled phase 3 trial (CREDIT-2). BMC Med. 2023;21(1):77.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Qi L, Liu D, Qu Y, Chen B, Meng H, Zhu L, Li L, Wang S, Liu C, Zheng G, et al. Tafolecimab in Chinese patients with hypercholesterolemia (CREDIT-4): a randomized, Double-Blind, Placebo-Controlled phase 3 trial. JACC Asia. 2023;3(4):636–45.

Article  PubMed  PubMed Central  Google Scholar 

Huo Y, Chen B, Lian Q, Wang S, Liu L, Lu D, Qu Y, Zheng G, Li L, Ji Y, et al. Tafolecimab in Chinese patients with non-familial hypercholesterolemia (CREDIT-1): a 48-week randomized, double-blind, placebo-controlled phase 3 trial. Lancet Reg Health West Pac. 2023;41:100907.

PubMed  PubMed Central  Google Scholar 

Shen H, Chai M, Zhou Y. Abstract 4136741: proprotein convertase subtilisin/kexin type 9 inhibitors and lipid reduction: a network Meta-Analysis. Circulation. 2024;150(Suppl1):A4136741–4136741.

Google Scholar 

Kastelein JJ, Ginsberg HN, Langslet G, Hovingh GK, Ceska R, Dufour R, Blom D, Civeira F, Krempf M, Lorenzato C, et al. ODYSSEY FH I and FH II: 78 week results with Alirocumab treatment in 735 patients with heterozygous Familial hypercholesterolaemia. Eur Heart J. 2015;36(43):2996–3003.

CAS  PubMed  PubMed Central  Google Scholar 

Hirayama A, Honarpour N, Yoshida M, Yamashita S, Huang F, Wasserman SM, Teramoto T. Effects of Evolocumab (AMG 145), a monoclonal antibody to PCSK9, in hypercholesterolemic, statin-treated Japanese patients at high cardiovascular risk–primary results from the phase 2 YUKAWA study. Circ J. 2014;78(5):1073–82.

Article  CAS  PubMed  Google Scholar 

Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R. Efficacy and safety of more intensive Lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–81.

Article  CAS  PubMed  Google Scholar 

Farnier M, Zeller M, Masson D, Cottin Y. Triglycerides and risk of atherosclerotic cardiovascular disease: an update. Arch Cardiovasc Dis. 2021;114(2):132–9.

Article  PubMed  Google Scholar 

Aberra T, Peterson ED, Pagidipati NJ, Mulder H, Wojdyla DM, Philip S, Granowitz C, Navar AM. The association between triglycerides and incident cardiovascular disease: what is optimal? J Clin Lipidol. 2020;14(4):438–e447433.

Article  PubMed  PubMed Central  Google Scholar 

Toth PP. Triglycerides and atherosclerosis: bringing the association into sharper focus. J Am Coll Cardiol. 2021;77(24):3042–5.

Article  CAS  PubMed  Google Scholar 

Raja V, Aguiar C, Alsayed N, Chibber YS, ElBadawi H, Ezhov M, Hermans MP, Pandey RC, Ray KK, Tokgözoglu L, et al. Non-HDL-cholesterol in dyslipidemia: review of the state-of-the-art literature and outlook. Atherosclerosis. 2023;383:117312.

Article  CAS  PubMed  Google Scholar 

Singh K, Prabhakaran D. Apolipoprotein B - An ideal biomarker for atherosclerosis? Indian Heart J. 2024;76(Suppl 1):S121–9.

Article  PubMed  PubMed Central  Google Scholar 

Behbodikhah J, Ahmed S, Elyasi A, Kasselman LJ, De Leon J, Glass AD, Reiss AB. Apolipoprotein B and cardiovascular disease: biomarker and potential therapeutic target. Metabolites 2021, 11(10).

Bittner VA, Szarek M, Aylward PE, Bhatt DL, Diaz R, Edelberg JM, Fras Z, Goodman SG, Halvorsen S, Hanotin C, et al. Effect of Alirocumab on Lipoprotein(a) and cardiovascular risk after acute coronary syndrome. J Am Coll Cardiol. 2020;75(2):133–44.

Article  CAS